Locations:
Search IconSearch

Vital Statistics in Thoracic Surgery, Lung Transplant and More

Our latest volumes and outcomes data in these areas plus HOCM and pericarditis

Below we share recent volumes and clinical outcomes from a sampling of disciplines and subspecialty areas in Cleveland Clinic’s Miller Family Heart, Vascular & Thoracic Institute: thoracic surgery, lung transplantation, hypertrophic obstructive cardiomyopathy and pericarditis.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

THORACIC SURGERY

2023 Data Highlights

2,016

Number of general thoracic operations performed

275

Number of robotically assisted thoracic surgery procedures

94%

Proportion of all lobectomies for stage I lung cancer (N = 120) that used video/robot-assisted thoracoscopic surgery

82.5%

Proportion of thymectomy/thymic mass resections completed robotically (N = 33)

STS Quality Ratings

The following data and ratings are from the Society of Thoracic Surgeons (STS) General Thoracic Surgery Database (3-year period ending December 2023):

data table showing lobectomy outcomes
data table showing lung cancer resection outcomes
data table showing esophagectomy outcomes
Of 106 rated participants in this STS category, Cleveland Clinic was one of 14 that achieved a three-star (highest) rating.

LUNG TRANSPLANTATION

2023 Data Highlights

129

Total lung transplants performed, including 1 heart/lung and 5 lung/liver

34

Lung transplants performed after ex vivo lung perfusion (EVLP)

97%

30-day survival rate following EVLP lung transplant

data table showing lung transplant survival rates

HOCM AND PERICARDITIS

2023 Data Highlights for Hypertrophic Obstructive Cardiomyopathy (HOCM)

4,847

Outpatient visits for HOCM

787

New HOCM patients seen

177

Septal myectomy procedures (with or without other procedures) performed for HOCM

0.0

Observed-to-expected mortality ratio for septal myectomy*

*According to Vizient® Clinical Data Base/Resource Manager. Used by permission of Vizient. All rights reserved.

2023 Data Highlights for Pericarditis

3,048

Patients seen by our Pericardial Diseases Center

573

New patients seen by the Pericardial Diseases Center

305

Pericardial procedures performed

56

Pericardiectomies performed

Cleveland Clinic’s Heart, Vascular & Thoracic Institute has a long-established tradition of reporting volume and outcomes data across its various subspecialty areas. For more information like the data reported above, visit clevelandclinic.org/hvtioutcomes and clevelandclinic.org/e15.

Advertisement

Related Articles

heart and lungs with a text overlay
Outcome Snapshots in Thoracic Surgery, Lung Transplant and More

Our latest performance data in these areas plus HOCM and pericarditis

Surgeon at robotic controls
January 9, 2026/Transplant/Innovation
Pushing Surgical Boundaries: Cleveland Clinic Abu Dhabi Debuts Robot-assisted Lung Transplants

Milestone minimally invasive surgeries reduce pain and recovery time

imaging study of the heart with scales of justice overlay balancing male and female symbols
Mavacamten’s Benefits Are Not Sex-Dependent and Include Sustained Cardiac Remodeling

End-of-treatment VALOR-HCM analyses reassure on use in women, suggest disease-modifying potential

Woman sleeping
October 29, 2025/Digestive/Research
Sleep Positioning Device Improves Lung Function in Transplant Recipients with GERD

Potentially cost-effective addition to standard GERD management in post-transplant patients

Dr. Zahka with a young patient
September 29, 2025/Pediatrics/Cardiology
New Insights About the Effects of Valsartan on Early-Stage Hypertrophic Cardiomyopathy

Cardiac imaging substudy is the latest paper originating from the VANISH trial

doctor explaining a heart model to a patient
Asymptomatic Hypertrophic Cardiomyopathy: Insights on Long-Term Outcomes and More

Vigilance for symptom emergence matters, a large 20-year analysis reveals

imaging study of a heart with nonobstructive hypertrophic cardiomyopathy
Myosin Inhibitor for Nonobstructive HCM: No Clinical Benefits but Positive Biomarker and Echo Effects

Phase 3 ODYSSEY-HCM trial of mavacamten leaves lingering questions about potential broader use

Ad